124
Participants
Start Date
June 26, 2014
Primary Completion Date
June 7, 2023
Study Completion Date
June 7, 2023
turoctocog alfa pegol
For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
National Taiwan University Children's Hospital, Taipei
Royal Children's Hospital, Parkville
LKH St. Poelten, Kinder-und Jugendheilkunde, Sankt Pölten
UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics, Plovdiv
Lady Cilento Children's Hospital, South Brisbane
A.O.U. Città della Salute e della Scienza di Torino-Ospedale, Torino
RAMA-Dept of Paediatrics, Bangkok
Hospital Pulau Pinang_Georgetown, Penang, George Town
North Shore Long Island Jewish Medical Center, New Hyde Park
Hospital Universitario La Paz, Madrid
Torrence Hemby Ped Hem/Onc Ctr, Charlotte
Werlhof-Institut, Hanover
Sunpasitthiprasong Hospital, Ubon Ratchathani
Maharaj Nakorn Chiang Mai Hospital -Pediatric Hematology and Oncology, Chiang Mai
Hospital Wanita dan Kanak-Kanak Kuala Lumpur, Kuala Lumpur
National Blood Centre, Kuala Lumpur
University Of Iowa, Iowa City
Sheba MC - The Israeli National Hemophilia Center, Tel Litwinsky
'Ippokrateio' General Hospital of Thessaloniki, Thessaloniki
Rush University Med. Cntr, Chicago
Univ Oklahoma Sci Ctr OK City, Oklahoma City
Univ of Utah Primary Children's Hospital, Salt Lake City
Children's Hospital Los Angeles - Endocrinology, Los Angeles
Arizona H&T Phoenix Child Hosp, Phoenix
Universitätsklinik für Kinder- und Jugendheilkunde, Vienna
Hamltn Hth Sci/McMstr Child Hosp, Hamilton
Aghia Sophia Childrens' Hospital, Athens
Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics, Kyoto
Shizuoka Children's Hospital, Hematology-Oncology, Shizuoka
National Center for Child Health and Development_Hematology, Tokyo
Hospital Sant Joan de Déu, Esplugues Llobregat
Lead Sponsor
Novo Nordisk A/S
INDUSTRY